• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Prednisolone and pentoxifylline do not reduce mortality in alcoholic hepatitis [STOPAH trial]

byAndrew Cheung, MD MBAandXu Gao
April 23, 2015
in Chronic Disease, Gastroenterology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In patients with severe alcoholic hepatitis, treatment with prednisolone or pentoxifylline did not significantly reduce mortality at 28 days. Moreover, these treatments did not reduce mortality or the need for liver transplantation at the 90-day or 1 year timepoints.

2. Patients treated with prednisolone experienced significantly higher rates of infections compared to those who were not.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Alcoholic hepatitis is a form of acute alcoholic liver disease that may result from prolonged and excessive alcohol consumption. Maddrey’s score is a commonly used prognostic tool to assess the severity of alcoholic hepatitis, which helps clinicians in determining whether or not such patients should be treated with adjuvant pharmacotherapy in the form of glucocorticoids or pentoxifylline. Previous randomized controlled trials have compared the effects of prednisolone and pentoxifylline with placebo in alcoholic hepatitis, though the results have been inconsistent. Moreover, little evidence exists comparing steroids and pentoxifylline directly in the treatment of alcoholic hepatitis, and the available results are conflicting.

The Steroids or Pentoxifylline for Alcoholic Hepatitis (STOPAH) trial sought to determine whether 28 days of prednisolone or pentoxifylline would alter short- and medium-term mortality in patients with severe alcoholic hepatitis. In summary, treating patients with severe alcoholic hepatitis with either prednisolone or pentoxifylline did not significantly reduce mortality at 28 days. Moreover, these treatments did not significantly reduce mortality or the need for liver transplantation at 90 days or 1 year, though treatment with prednisolone was associated with significantly higher risk of infection.

Click to read the study, published today in NEJM

Relevant Reading: Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: A randomized clinical trial

RELATED REPORTS

Direct-acting antiviral agents significantly lower Hepatitis C related mortality and cancer risk

Bepirovirsen may reduce disease burden in patients with chronic hepatitis B

Heavy smoking and alcohol use may be associated with insomnia and sleep dissatisfaction

In-Depth [randomized controlled trial]: This multicenter, randomized controlled trial employed a 2×2 factorial design. A total of 1103 patients were recruited from 65 sites from across the United Kingdom. Patients were included if they were ≥18 years of age, were clinically diagnosed with alcoholic hepatitis, consumed >80 g/day of alcohol for men or >60 g/day for women, had a serum bilirubin >80 ÎĽmol/L, and a Maddrey score ≥32. Exclusion criteria included jaundice for >3 months, cessation of alcohol consumption >2 months prior to randomization, the presence of other causes of liver disease, renal failure, active gastrointestinal bleeding, untreated sepsis, or requirement of inotropic support. Eligible patients were randomized to one of the following treatment arms: 1) placebo, 2) prednisolone 40 mg daily, 3) pentoxifylline 400 mg three times daily, 4) both prednisolone and pentoxifylline. All patients were treated for 28 days and the primary endpoint was 28-day mortality. Secondary endpoints were mortality or liver transplantation at 90 days and 1 year. All patients were followed for 12 months or until they died.

At 28 days, there was no significant difference in mortality when comparing patients who were treated with pentoxifylline with those who were not (OR 1.07; 95%CI 0.77-1.49; p = 0.69). There was also no difference in 28-day mortality when comparing patients treated with prednisolone and those who were not (OR 0.72; 95%CI 0.52-1.01; p = 0.06). Moreover, neither treatment impacted mortality or the need for liver transplantation at 90 days or 1 year. The risk of infection was significantly higher in patients treated with prednisolone (p = 0.002).

Image: CC/Wiki/Nephron

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Alcoholhepatitispentoxifyllinesteroids
Previous Post

Mindfulness-based cognitive therapy is not superior to maintenance antidepressants in preventing depression recurrence or relapse [PREVENT trial]

Next Post

Substance use linked with increased mortality in individuals released from prison

RelatedReports

Prognostic indicators for transarterial chemoembolization in patients with hepatocellular carcinoma with extrahepatic spread identified
Gastroenterology

Direct-acting antiviral agents significantly lower Hepatitis C related mortality and cancer risk

December 23, 2022
Spleen elastography may be effective in the diagnosis of portal hypertension
Chronic Disease

Bepirovirsen may reduce disease burden in patients with chronic hepatitis B

December 22, 2022
E-interventions linked to short-term reduction in alcohol consumption in college students
Chronic Disease

Heavy smoking and alcohol use may be associated with insomnia and sleep dissatisfaction

November 18, 2022
Plagiocephaly/brachycephaly associated with lower cognitive and academic achievement scores
Wellness

Wellness Check: Sleep

November 17, 2022
Next Post
PD

Substance use linked with increased mortality in individuals released from prison

New chemotherapy precludes the need for radiotherapy in primary mediastinal B-cell lymphoma

Pazopanib plus paclitaxel may increase survival in platinum-resistant ovarian cancer

Adjuvant breast cancer treatment associated with additional cancer risk

Oophorectomy linked to decreased mortality in BRCA1 breast cancer

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
  • Homicide deaths are on the rise for children living in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options